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The propensity of retroviruses to rapidly establish persistent infections poses a formidable problem in vaccination
strategies. In the current study, we use a live attenuated vaccine to study protection against acute and persistent Friend virus
infections in mice. Adoptive transfers of immune CD81 T cells combined with passive immunizations with virus-neutralizing
antibodies increased protection against acute disease compared with either treatment alone, but there was no protection
against the establishment of persistent infection. In addition, the protection against acute disease elicited by the combination
treatment was dependent on endogenous CD41 T cells as no protection was achieved in CD41 T-cell-depleted mice.
Quantitative studies showed that doubling the numbers of immune lymphocytes used in adoptive transfer experiments
increased protection against acute disease depending on the type of lymphocyte subset used in the transfer. CD81 T cells
were the most potent subset for the transfer of such protection. However, even high numbers of immune CD81 T cells gave
no protection against the establishment of persistent infections. The data indicate that strengthening the numbers of specific
immune cell subsets may have a beneficial effect on protection against acute disease, but protection from establishment of
persistence requires complex immune responses involving multiple lymphocyte subsets. © 2000 Academic Press
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CINTRODUCTION
Live attenuated vaccines have been proved to be the
most effective approach to inducing protection against
pathogenic retroviruses, but such vaccines are consid-
ered too dangerous for use in humans (Baba et al., 1995,
1999; Berkhout et al., 1999; Cohen, 1997; Dittmer, 1997).
onetheless, it is important to understand why these
accines are so effective, and animal studies provide a
owerful way to investigate basic mechanisms of pro-
ection against retrovirus-induced diseases. We previ-
usly used the Friend virus (FV) model to investigate
hich types of immune lymphocytes were necessary for
he protective immunity induced by vaccination with a
ive-attenuated retrovirus (Dittmer et al., 1999b). FV is a
etroviral complex composed of two components: a rep-
ication-competent helper virus called Friend murine leu-
emia virus (F-MuLV), which is nonpathogenic in adult
ice; and a replication-defective but pathogenic compo-
ent called spleen focus-forming virus (SFFV) (Kabat,
989). The infection of adult mice with FV complex in-
uces an acute disease characterized by splenomegaly
ue to rapid polyclonal erythroblast proliferation. This is
1 Present address: Institut fuer Virologie der Universitaet Wuerzburg,
uerzburg, Germany. Fax: 49-931-2013934. E-mail: ulf.dittmer@mail.uni-
uerzburg.de.r
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177ollowed within several weeks by the development of
ethal erythroleukemia (Hoatlin and Kabat, 1995; Li et al.,
990; Moreau-Gachelin et al., 1988; Munroe et al., 1990;
endling and Tambourin, 1978). In contrast, infection
ith only the F-MuLV helper virus results in poor virus
eplication and the induction of immune responses that
re protective against subsequent challenge with FV
omplex (Dittmer et al., 1998, 1999c). Thus F-MuLV helper
irus acts as an attenuated retroviral vaccine. Vaccination
ith F-MuLV has been shown to protect mice against acute
linical signs of disease such as splenomegaly and viremia
Dittmer et al., 1998) and protects against the establishment
f low-level persistent infections that can later reactivate
nd become pathogenic (Dittmer et al., 1999a).
Previous experiments showed that adoptively trans-
erred spleen cells from mice immunized with F-MuLV
ere able to protect naive mice from acute FV-induced
plenomegaly (Dittmer et al., 1998). Furthermore, adop-
ive transfer experiments with purified spleen cell sub-
ets indicated that immunological protection against FV-
nduced splenomegaly required complex immune re-
ponses involving all three major lymphocyte subsets:
D41 T cells (“helper” T cells); CD81 T cells [cytolytic T
lymphocytes (CTLs)], and B cells (antibody-producing
cells) (Dittmer et al., 1999b). There was a partially pro-
tective effect in mice that received adoptive transfers of
CD81 T cells: the mice became splenomegalic but later
ecovered and did not progress to erythroleukemia.
owever, those mice remained persistently infected.
0042-6822/00 $35.00
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178 DITTMER AND HASENKRUGTransfers of immune B cells alone did not provide even
partial protection, although passive immunization with
virus-neutralizing antibodies before virus challenge sig-
nificantly reduced levels of spleen virus (Dittmer et al.,
999b). We found that the transferred immune B cells did
ot produce detectable virus-neutralizing antibodies until
hey received antigenic restimulation by virus challenge
n vivo (Dittmer et al., 1999b). Thus the transferred B cells
ay have been predominantly memory cells rather than
ully differentiated, antibody-producing plasma cells
Slifka et al., 1998). Alternatively, there may have been
nsufficient numbers of B cells in the adoptive transfers
o reach our threshold of antibody detection.
These efforts to dissect the immunological compo-
ents of induced immunity raised two important ques-
ions that the current experiments were designed to test.
irst, could the transfer of a combination of both CD81 T
cells and virus-neutralizing antibodies mediate complete
protection, defined as protection from the establishment
of low-level persistent infections as well as acute clinical
signs? Second, could quantitative increases in the num-
bers of single immune lymphocyte subsets or increases
in the dose of virus-neutralizing antibodies compensate
for the lack of one subset or another?
RESULTS
A combination of neutralizing antibodies and immune
CD81 T cells does not completely prevent
cute FV-induced disease
In our previous experiments, we observed that im-
une CD81 T cells and virus-neutralizing antibodies
ould both reduce viral loads in FV-infected mice and
acilitate recovery from acute splenomegaly in most of
he recipients (Dittmer et al., 1999b). To determine
hether adoptive transfer of vaccine-primed CD81 T
ells combined with passive immunization would prevent
V-induced disease, naive mice were transplanted with
urified immune CD81 T cells and were passively immu-
ized with envelope-specific, virus-neutralizing monoclo-
al antibody 1 day before challenge with pathogenic FV.
he number of CD81 T cells (0.9 3 107) was based on the
approximate number of CD81 T cells present in a pro-
ective dose of whole immune spleen cells (5 3 107) from
F-MuLV-immunized mice (Dittmer et al., 1999b). The an-
tibody dose (32 mg) was based on matching the virus-
neutralizing antibody titers found in F-MuLV-vaccinated
mice (Dittmer et al., 1999b). The combination treatment
protected two of six mice from acute splenomegaly, and
the other four mice recovered by 5 weeks after challenge
(Fig. 1). However, all six mice harbored persistent virus in
their spleens at 3 months postchallenge as determined
by infectious center assays on spleen cells (data not
shown). Thus the combination treatments did not prevent
or completely clear the FV infections.
To determine whether the unprimed CD41 T cells fromthe recipient mice played any role in the recovery of mice
receiving the combination treatment, a group of recipi-
ents were depleted of their CD41 T cells before transfers
of CD81 T cells and virus-neutralizing antibodies. Inter-
estingly, protection from virus challenge was completely
dependent on the endogenous CD41 T cells in the re-
cipient mice in that all mice in this group developed
severe, nonresolving splenomegaly (Fig. 1). These data
indicated that unprimed CD41 T cells either had a direct
antiviral effect or provided immunological help for re-
sponses such as CTL or B-cell responses.
The quantity of immune lymphocytes influences
protection against acute FV infection
To test the possibility that higher quantities of single
lymphocyte subsets might influence protection, we trans-
ferred twice as many purified immune cells as present in
a protective dose of whole immune spleen cells (Dittmer
et al., 1999b). At 2 weeks postchallenge, the severity of
splenomegaly in each mouse was measured on a scale
from 1(normal) to 4 (very severe splenomegaly) (Hasen-
krug, 1998). All recipients that received immune CD41 T
cells, regardless of the cell number transferred, had
severe to very severe FV-induced splenomegaly at this
time point (Fig. 2). Thus high numbers of adoptively
transferred CD41 T cells were not protective. In contrast,
none of the mice adoptively transferred with the high
number of immune CD81 T cells were splenomegalic,
whereas the mice that received lower numbers of CD81
cells had at least moderate FV-induced splenomegaly
FIG. 1. Combined transfer of immune CD81 T cells and FV-neutral-
izing antibodies. Purified immune CD81 T cells were obtained as
reviously described (Dittmer et al., 1999b) from (B10.A 3 A.BY)F1 mice
accinated with live-attenuated N-tropic F-MuLV 30 days before (Ditt-
er et al., 1998), and 9 3 106 CD81 cells were transferred into each
aive syngeneic recipient. In addition, these mice received passive
mmunization with 32 mg of F-MuLV env-specific mAb 48 before chal-
enge (Hasenkrug et al., 1995) (D). One group of six mice that received
D81 cells and mAb 48 was depleted of CD4 cells by mAb 191.1 as
described (F) (Hasenkrug et al., 1996). These mice had less than 1%
CD41 T cells at the time of challenge. All recipients were challenged
ith 3000 SFFU of pathogenic B-tropic, polycythemia-inducing FV com-
lex. After virus challenge, mice were palpated for splenomegaly as
escribed previously (Chesebro et al., 1974; Hasenkrug, 1998b).(Fig. 2). Thus there was a significant effect on spleno-
megaly when higher numbers of immune CD81 T cells
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179PROTECTION BY ATTENUATED RETROVIRAL VACCINESwere transferred. Mice receiving high numbers of im-
mune CD191 B cells tended toward less severe spleno-
egaly than mice receiving the lower number of B cells,
ut there was a wide range in the responses of the mice
Fig. 2). We also tested the effects of increasing the dose
f virus-neutralizing monoclonal antibody (mAb 48) used
or passive immunizations. There was a dramatic effect
n the mice receiving a high dose of virus-neutralizing
onoclonal antibody. None of those mice showed FV-
nduced splenomegaly, whereas all mice receiving the
ower dose of antibody developed moderate to severe
plenomegaly (Fig. 2).
As an additional measure of virus replication and
pread, plasma samples from recipient mice were ana-
yzed for the presence of free virus. The results essen-
ially mirrored the splenomegaly data. The groups that
eceived high numbers of CD81 T cells or high doses of
virus-neutralizing monoclonal antibodies were protected
from viremia; the mice receiving high numbers of CD191
B cells had variable responses; and there was no signif-
icant protection from adoptive transfers of high numbers
of CD41 T cells compared with the control mice adop-
tively transferred with naive spleen cells (Fig. 3).
Only a combination of all three lymphocyte subsets
protected mice against establishment of persistent
FV infections
FIG. 2. Severity of splenomegaly in individual mice receiving adop-
tive transfers or passive immunizations. Mice were treated as indicated
and challenged with pathogenic FV as in Fig. 1. Splenomegaly in
individual mice was rated on a scale ranging from 1 (normal) to 4 (very
severe) as described previously (Hasenkrug, 1998b). Each increasing
numerical value represents an approximate doubling of spleen size.Achieving vaccine protection against the establish-
ment of persistent FV infection has been shown to be
t
omuch more difficult than protection against clinical signs
of acute disease such as splenomegaly or viremia (Ditt-
mer et al., 1999a). FV persistence is established very
quickly in a small number of cells, predominantly B cells,
that evade CTL killing in an unknown manner (Hasenk-
rug et al., 1998a). Thus the kinetics of the development of
protective immune responses is a critical factor in
achieving protection against persistent FV infection. To
test for protection against persistent FV infection, the
adoptively transferred mice that were protected from
acute disease or that became ill but then recovered were
sacrificed and analyzed for persistent spleen virus by
infectious center assays. All except one of the control
mice that received whole immune spleen cells were
protected against persistent FV (Fig. 4). We previously
demonstrated by a sensitive in vivo bioassay that simi-
larly treated mice contained no pathogenic virus (Dittmer
et al., 1999a,b). In contrast, all of the mice that received
high numbers of CD81 T cells had relatively high levels
of persistent virus in their spleens (Fig. 4). In the group
that received CD191 B cells, the levels were variable but
tended to be lower than the CD81 T-cell transfer group,
and one mouse had no detectable persistent virus. The
group that was passively immunized with high concen-
trations of virus-neutralizing monoclonal antibody had
the lowest levels of infectious centers in their spleen
cells, but persistent virus was still detectable in all of the
mice (Fig. 4).
DISCUSSION
The current results show that it is possible to prevent
acute FV-induced splenomegaly and viremia in mice by
FIG. 3. Plasma viremia in FV-challenged mice that received high
numbers of immune lymphocyte subsets or a high concentration of
virus-neutralizing mAb 48. Individual plasma samples were taken at 8
days postchallenge to assay for the presence of viremia as described
previously (Dittmer et al., 1999b; Sitbon et al., 1985). The lower limit of
etection for this assay was 220 FFU/ml of plasma. “Transfers” indi-
ates the type of transfer in each group, and “Cell numbers” indicateshe numbers of transferred cells or, in the case of mAb 48, the amount
f monoclonal antibody injected.
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180 DITTMER AND HASENKRUGusing solely cellular or humoral immunity. The critical
feature for such protection was the quantity of antiviral
CD81 T cells or FV-neutralizing antibodies, respectively.
ecause immune CD41 T cells alone had no effect on
V-induced disease or viremia levels, these cells did not
eem to have direct antiviral effector functions during the
cute phase of infection. However, they were very im-
ortant to provide immunological help for FV-specific
ffectors because no protection was achieved in the
bsence of endogenous CD41 T cells, even when a
ombination of CD81 T cells and FV-neutralizing antibod-
ies was transferred (Fig. 1). Interestingly, the protection
achieved by transfers of primed CD81 T cells or virus-
eutralizing antibody did not extend to protection from
he establishment of FV persistence, although whole
mmune spleen cells did provide such protection. In this
espect, previous results showed that half as many im-
une CD81 could protect against persistent FV if com-
ined with CD41 T and B cells (Dittmer et al., 1999b).
These results underscore the beneficial effects of having
multiple types of immune responsiveness.
Although persistent FV infections result in only a 5%
incidence of virus reactivations and relapse of erythro-
leukemia (Chesebro et al., 1979), the incidence increases
to approximately 50% in mice experimentally depleted of
CD41 T cells (Hasenkrug et al., 1998a). In humans, im-
unosuppressive drugs or viral infections can also re-
ctive persistent infections. Of particular concern are
nfections with hepatitis B virus, human cytomegalovirus,
uman T cell leukemia viruses, and human immunode-
iciency virus (HIV) (Ciurea et al., 1999). Ideally, vaccines
hould achieve protection against both acute disease
nd persistent infections. We found that this level of
FIG. 4. Persistent spleen virus in mice surviving FV challenge. Spleen
cell-associated viral loads (infectious centers) are shown at 8 weeks
after FV challenge from individual animals receiving whole immune
spleen cells, different lymphocyte subsets from F-MuLV-vaccinated
mice, or mAb 48. The lower limit of detection was one infectious
center/107 spleen cells. The numbers of cells transferred per group
were 5 3 107 immune spleen cells, 1.8 3 107 CD81 cells, and 4 3 107
CD191 cells (B cells). The concentration of mAb 48 injected was 875
mg/mouse.rotection was attainable in the FV model by vaccination
ith a live attenuated virus (Dittmer et al., 1999a), and theurrent adoptive transfer experiments show that a key
spect of such protection is the priming of all three major
ymphocyte subsets. Experiments in the lymphocytic
horiomeningitis virus model have also pointed to re-
uirements for complex immune responses (Planz et al.,
997), although an earlier report indicated that CD81 T
ells were sufficient for protection (Oldstone et al., 1993).
These results are consistent with the types of func-
ions performed by each of the lymphocyte subsets dur-
ng retroviral infections. High quantities of antibody-se-
reting B cells or virus-neutralizing antibodies may have
owered levels of persistent virus (Fig. 4) because anti-
odies can neutralize virus before cells become infected.
owever, although neutralizing antibodies are effective
t clearing free retroviruses from the blood (Britt and
hesebro, 1983; Igarashi et al., 1999), it requires ex-
remely high titers of antibody to completely prevent
etroviral infections (Dittmer et al., 1999b; Moore and
urton, 1999; Shibata et al., 1999). Furthermore, antibod-
es do not appear to be effective at eliminating retrovirus-
nfected cells (Hasenkrug et al., 1995; Poignard et al.,
999). On the other hand, CD81 CTL cannot reduce the
titer of the initial virus inoculum, but they are able to
eliminate infected cells. The CD41 T cells are critical
ecause both the humoral and the CD81 CTL responses
are dependent on T-cell help (Dittmer et al., 1999b; Super
et al., 1998) (Fig. 1). The live attenuated virus vaccine is
so effective because it not only elicits broad immune
responses (antibody, to limit the number of initially in-
fected cells; CTLs, to eliminate the breakthrough infec-
tions; and CD41 T cell help, to facilitate both effector
arms) but also elicits quantitatively high levels of respon-
siveness in each arm of the immune system. The impor-
tance of the quantitative aspects is evident from our
results in which the numbers of immune cells were
doubled (Figs. 2 and 3). For long-term protection, the
maintenance of virus-neutralizing antibodies is probably
especially important because the ability of antibodies to
limit initial infection provides time for the cell-mediated
responses to expand from memory populations. We have
previously shown that vaccination with live attenuated FV
generates solid protection for up to 6 months after vac-
cination, showing that good immunological memory was
generated (Dittmer et al., 1999c).
Our current results might have relevance for vaccine
development against human retroviruses such as HIV.
The difficulties in generating HIV-specific virus-neutraliz-
ing antibodies have prompted efforts to obtain CTL-
based vaccines. Our results imply that it may be very
difficult to generate protective vaccines that exclusively
stimulate single arms of the immune system, especially
if one expects to protect against the establishment of
persistent HIV infections that eventually lead to AIDS.
Like FV, HIV establishes persistence very early in the
course of infection, even in the face of highly active
antiviral therapy (Chun et al., 1997, 1998; Finzi et al.,
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181PROTECTION BY ATTENUATED RETROVIRAL VACCINES1997). Although we feel that it is unlikely to achieve full
protection against HIV using narrowly based vaccine
strategies, it may be possible that such vaccines reduce
steady state virus loads (viral set points) and thus pro-
long the asymptomatic phase of HIV infections (Mellors
et al., 1996). However, strategies for attaining sterilizing
immunity should focus on the difficult tasks of eliciting
high levels of neutralizing antibodies combined with
strong immunological memory in all three major lympho-
cyte subsets.
MATERIALS AND METHODS
Mice
(B10.A 3 A.BY)F1 female mice at 3–6 months old at
xperimental onset were used for all experiments. Pa-
ental mouse strains for breeding F1 mice were obtained
rom Jackson Laboratories. Breeding of F1 strains was
one at Rocky Mountain Laboratories. All mice were
reated in accordance with National Institutes of Health
egulations and the guidelines of the Animal Care and
se Committee of Rocky Mountain Laboratories.
accination and virus challenge
The B-tropic, polycythemia-inducing FV complex used
s challenge virus in all experiments was from uncloned
irus stocks obtained from 10% spleen cell homogenates
s described by Hasenkrug (1998). The N-tropic F-MuLV
accine virus (stock 29-51N) (Chesebro et al., 1983) was
24-h supernatant from infected Mus dunni cells. Mice
ere vaccinated by injecting intravenously 0.5 ml of
hosphate-buffered balanced salt solution (PBBS) con-
aining 2% fetal bovine serum (FBS) and 104 focus-form-
ing units (FFU) of F-MuLV vaccine virus. In all virus
challenge experiments, mice were injected intravenously
with 0.5 ml of PBBS containing 2% FBS and 3000 spleen
focus-forming units (SFFU) of pathogenic FV complex.
Disease was followed by palpation for splenomegaly in a
blinded fashion as described by Hasenkrug (1998b).
Adoptive spleen cell transfers
For the transfer experiments, (B10.A 3 A.BY)F1 mice
(Fv-1b/b) were vaccinated by infection with 104 FFU of
ive-attenuated N-tropic F-MuLV. After 30 days, spleen
ells from these mice were pooled and adoptively trans-
erred to naive syngenic animals. Each mouse received
n intravenous injection of 0.5 ml of PBBS containing 2%
BS, 15 U/ml heparin, and the indicated numbers of
pleen cells or purified lymphocyte subsets. One day
fter transfer, the recipients were challenged with 3000
FFU of pathogenic polycythemia-inducing, B-tropic FV.
group of controls received 5 3 107 spleen cells from
naive mice. After FV challenge, the recipients were mon-
itored weekly for virus-induced splenomegaly as de-
scribed by Hasenkrug (1998b).Enrichment of lymphocyte subsets
The MidiMACS Separation System (Miltenyi Biotech,
Bergisch Gladbach, Germany) was used for the purifica-
tion of lymphocyte subsets as previously described (Ditt-
mer et al., 1999b). Briefly, CD41, CD81, and CD191 cells
B cells) were labeled with paramagnetic MicroBeads
Miltenyi Biotech) before immunomagnetic separation.
he purity of the cell fractions was monitored by flow
ytometry. The purity of the enriched B cell fraction was
8.6%. The enriched T-cell subsets were 96.4% pure for
D41 and 92.1% pure for CD81 cells. All cell fractions
contained less than 5% dead cells after the separation
procedure.
T-cell depletions
T-cell depletions were performed essentially as de-
scribed by Hasenkrug et al. (1995). Briefly, mice were
inoculated intraperitoneally with 0.5 ml of supernatant
fluid obtained from artificial capillary cultures (Cellco,
Germantown, MD) of hybridoma 191.1 (anti-CD4, rat anti-
mouse IgG2b isotype) (Cobbold et al., 1984). Mice were
inoculated three times per week for a total of five injec-
tions.
Viremia and infectious center assays
For viremia assays, freshly frozen plasma samples
were titrated by focal infectivity assays as described
previously (Dittmer et al., 1998; Sitbon et al., 1985). Infec-
tious centers from spleens were detected by titrations of
single-cell suspensions onto susceptible Mus dunni
cells as described by Dittmer et al. (1998).
mAb 48 passive transfers
mAb 48 is a mouse monoclonal IgG2a specific for
F-MuLV gp70 envelope (Chesebro et al., 1981), and su-
pernatants were prepared from a Cellmax artificial cap-
illary system (Georgetown, MD). Supernatant (0.5 ml) at
indicated dilutions was injected intraperitoneally two
times, on days 23 and 21 relative to virus challenge, to
give the amount of antibody indicated in the figures.
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